The concern of generic competition has long loomed above copyright’s blockbuster drug, Viagra, sparking questions about the outlook of connected pharmaceutical ventures. While initial times saw impressive returns, the exclusivity lapse has opened the way for less expensive copies, potentially diminishing profitability and posing a genuine risk fo